1. Guide to Atopic Dermatitis

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Atopic Dermatitis

4. What Is Atopic Dermatitis?

5. Patient Case Julien, 43-Year-Old Male

6. Patient Case: Julien Assessment and Confirmation of AD

7. Patient Case: Julien Identify Degree of Severity

8. Assessing Severity Clinical Trial and Practice Setting

9. Practical Engagement of the Patient

10. When Is Systemic Therapy Appropriate?

11. Begin Shared Decision-Making

12. Pharmacologic Therapies

13. Patient Case (cont)

14. Decision 'Tree' Is Dupilumab the Right Choice?

15. Defining Treatment Failure

16. Insurance Documentation

17. Managing Systemic Treatment

18. European vs US Access to Dupilumab

19. Management Approach to Pediatric Patients

20. Supporting Pediatric Patients Parental Education

21. Concluding Remarks

22. Abbreviations